PDUFA Needs More Than 300 Additional FTEs, New US FDA Capacity Planning Formula Says
Executive Summary
But the agency chose to fund only a small fraction of them, in part because of its hiring ability, and in part because all those employees would have cost an additional $98.7m in user fee revenue.
You may also be interested in...
US FDA Personnel Costs Drop: Is The Next Generation Taking Over?
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
FY 2019 Drug Development Drives FY 2021 User Fees Lower
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.
US FDA Sets FY 2021 User Fees, With Coronavirus (Somewhat) In Mind
ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: